NVCT
Q3 2026 EPS Estimate
$-0.25
Aug 4, 2026 · Reports before open
FY2029E EPS$0.60
FY2030E EPS$2.72

Analyst Sentiment

Wall St. Consensus
Buy
2 analysts·Low coverage
75
Score
2 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$39.00
+99.8%
Consensus
$39.00
+99.8%
Bull
$39.00
+99.8%
12-Month Target Range2 analysts
$39.00$39.00$39.00
Current $19.52Consensus
Current Price
$19.52
Upside to Consensus
$19.48

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+779.60%
EPS
FY2028
Rev-55.90%
EPS
FY2029
Rev+911.71%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$3M$26M$11M$116M$193M
Low$3M$26M$11M$116M$193M
High$3M$26M$11M$116M$193M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-23M$-23M$-30M$13M$59M
Low$-23M$-25M$-40M$13M$59M
High$-22M$-21M$-19M$13M$59M
EPS Avg$-1.04$-1.06$-1.40$0.60$2.72
Low$-1.08$-1.16$-1.84$0.60$2.72
High$-0.99$-0.96$-0.88$0.60$2.72
Analysts (Rev / EPS)5 / 45 / 45 / 42 / 22 / 2
Quarterly
MetricQ3 2026Q4 2026
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-6M$-6M
Low$-6M$-6M
High$-6M$-6M
EPS Avg$-0.26$-0.25
Low$-0.27$-0.25
High$-0.25$-0.25
Analysts (Rev / EPS) / 3 / 1

Earnings Surprises

Recent Analyst Actions

Jun 22, 2026H.C. Wainwright
Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright
Target:$39.00
+160.7%from $14.96
Jun 12, 2026H.C. Wainwright
Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright
Target:$13.00
+21.9%from $10.67
Aug 4, 2025H.C. Wainwright
Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright
Target:$10.00
+37.2%from $7.29
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.